GRAIL (GRAL) Expected to Announce Earnings on Tuesday

GRAIL (NASDAQ:GRAL) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect GRAIL to post earnings of ($3.14) per share and revenue of $37.57 million for the quarter.

GRAIL (NASDAQ:GRAL) last released its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.93. The company had revenue of $31.84 million during the quarter, compared to analyst estimates of $35.80 million. GRAIL had a negative net margin of 1,464.53% and a negative return on equity of 17.99%. On average, analysts expect GRAIL to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

GRAIL Trading Down 0.4%

GRAIL stock opened at $32.82 on Friday. The firm has a 50 day moving average of $40.70 and a 200 day moving average of $36.09. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -0.54 and a beta of 3.26. GRAIL has a 12-month low of $12.33 and a 12-month high of $63.99.

Insiders Place Their Bets

In other news, President Joshua J. Ofman sold 9,692 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $52.00, for a total transaction of $503,984.00. Following the completion of the transaction, the president directly owned 492,076 shares in the company, valued at approximately $25,587,952. This represents a 1.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Chun R. Ding sold 339,800 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $49.53, for a total value of $16,830,294.00. Following the transaction, the insider owned 3,305,055 shares of the company’s stock, valued at $163,699,374.15. This represents a 9.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 357,492 shares of company stock worth $17,645,718 in the last three months. 1.85% of the stock is owned by company insiders.

Institutional Trading of GRAIL

Institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after buying an additional 1,401 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the period. Royal Bank of Canada increased its stake in GRAIL by 17.7% in the first quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in GRAIL by 37.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after purchasing an additional 25,177 shares during the period.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group upped their price target on GRAIL from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.